394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results

394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results

Bibliographic Details
Main Authors: Ignacio Melero, Diwakar Davar, Emiliano Calvo, Donald Richards, Sarina Piha-Paul, Matthew Dallos, Martin Gutierrez, Matteo Simonelli, Jason Melear, Janaki Parameswaran, Vinit Kumar, Xiaochen Zhao, Santanu Dutta
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
id doaj-166aa176ac0146108e01f9deabb0d781
record_format Article
spelling doaj-166aa176ac0146108e01f9deabb0d7812020-12-11T10:01:51ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0394394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 resultsIgnacio Melero0Diwakar Davar1Emiliano Calvo2Donald Richards3Sarina Piha-Paul4Matthew Dallos5Martin Gutierrez6Matteo Simonelli7Jason Melear8Janaki Parameswaran9Vinit Kumar10Xiaochen Zhao11Santanu Dutta129Universidad de Navarra, Pamplona, Spain1University of Pittsburgh Medical Center, Pittsburgh, PA, USA4START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain5Texas Oncology, US Oncology Research, Austin, TX, USA1MD Anderson Cancer Center, Houston, TX, USA7Columbia University Medical Center, New York, NY, USA3Hackensack University Medical Center, Hackensack, NJ, USA2Humanitas University; Humanitas Cancer Center – Humanitas Research Hospital, Milan, Italy5Texas Oncology, US Oncology Research, Austin, TX, USA8Bristol Myers Squibb, Princeton, NJ, USA8Bristol Myers Squibb, Princeton, NJ, USAMedical Affairs, 3D Medicines Inc, Shanghai, China8Bristol Myers Squibb, Princeton, NJ, USA
collection DOAJ
language English
format Article
sources DOAJ
author Ignacio Melero
Diwakar Davar
Emiliano Calvo
Donald Richards
Sarina Piha-Paul
Matthew Dallos
Martin Gutierrez
Matteo Simonelli
Jason Melear
Janaki Parameswaran
Vinit Kumar
Xiaochen Zhao
Santanu Dutta
spellingShingle Ignacio Melero
Diwakar Davar
Emiliano Calvo
Donald Richards
Sarina Piha-Paul
Matthew Dallos
Martin Gutierrez
Matteo Simonelli
Jason Melear
Janaki Parameswaran
Vinit Kumar
Xiaochen Zhao
Santanu Dutta
394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results
Journal for ImmunoTherapy of Cancer
author_facet Ignacio Melero
Diwakar Davar
Emiliano Calvo
Donald Richards
Sarina Piha-Paul
Matthew Dallos
Martin Gutierrez
Matteo Simonelli
Jason Melear
Janaki Parameswaran
Vinit Kumar
Xiaochen Zhao
Santanu Dutta
author_sort Ignacio Melero
title 394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results
title_short 394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results
title_full 394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results
title_fullStr 394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results
title_full_unstemmed 394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results
title_sort 394 interleukin-8–neutralizing monoclonal antibody bms-986253 plus nivolumab (nivo) in biomarker-enriched, primarily anti–pd-(l)1–experienced patients with advanced cancer: initial phase 1 results
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2020-11-01
work_keys_str_mv AT ignaciomelero 394interleukin8neutralizingmonoclonalantibodybms986253plusnivolumabnivoinbiomarkerenrichedprimarilyantipdl1experiencedpatientswithadvancedcancerinitialphase1results
AT diwakardavar 394interleukin8neutralizingmonoclonalantibodybms986253plusnivolumabnivoinbiomarkerenrichedprimarilyantipdl1experiencedpatientswithadvancedcancerinitialphase1results
AT emilianocalvo 394interleukin8neutralizingmonoclonalantibodybms986253plusnivolumabnivoinbiomarkerenrichedprimarilyantipdl1experiencedpatientswithadvancedcancerinitialphase1results
AT donaldrichards 394interleukin8neutralizingmonoclonalantibodybms986253plusnivolumabnivoinbiomarkerenrichedprimarilyantipdl1experiencedpatientswithadvancedcancerinitialphase1results
AT sarinapihapaul 394interleukin8neutralizingmonoclonalantibodybms986253plusnivolumabnivoinbiomarkerenrichedprimarilyantipdl1experiencedpatientswithadvancedcancerinitialphase1results
AT matthewdallos 394interleukin8neutralizingmonoclonalantibodybms986253plusnivolumabnivoinbiomarkerenrichedprimarilyantipdl1experiencedpatientswithadvancedcancerinitialphase1results
AT martingutierrez 394interleukin8neutralizingmonoclonalantibodybms986253plusnivolumabnivoinbiomarkerenrichedprimarilyantipdl1experiencedpatientswithadvancedcancerinitialphase1results
AT matteosimonelli 394interleukin8neutralizingmonoclonalantibodybms986253plusnivolumabnivoinbiomarkerenrichedprimarilyantipdl1experiencedpatientswithadvancedcancerinitialphase1results
AT jasonmelear 394interleukin8neutralizingmonoclonalantibodybms986253plusnivolumabnivoinbiomarkerenrichedprimarilyantipdl1experiencedpatientswithadvancedcancerinitialphase1results
AT janakiparameswaran 394interleukin8neutralizingmonoclonalantibodybms986253plusnivolumabnivoinbiomarkerenrichedprimarilyantipdl1experiencedpatientswithadvancedcancerinitialphase1results
AT vinitkumar 394interleukin8neutralizingmonoclonalantibodybms986253plusnivolumabnivoinbiomarkerenrichedprimarilyantipdl1experiencedpatientswithadvancedcancerinitialphase1results
AT xiaochenzhao 394interleukin8neutralizingmonoclonalantibodybms986253plusnivolumabnivoinbiomarkerenrichedprimarilyantipdl1experiencedpatientswithadvancedcancerinitialphase1results
AT santanudutta 394interleukin8neutralizingmonoclonalantibodybms986253plusnivolumabnivoinbiomarkerenrichedprimarilyantipdl1experiencedpatientswithadvancedcancerinitialphase1results
_version_ 1724386532589043712

Similar Items